Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04411628 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
A Phase 1 study of COVID-19, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 11
- Study locations
NCT04411628 is a Phase 1 study of COVID-19 that has completed, run by Eli Lilly and Company. The registered enrollment target is 26 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT04411628, a Phase 1 study of COVID-19, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3819253
Study Locations (11)
California
- Cedars Sinai Medical Center - Los Angeles
- Veterans Affairs Medical Center San Diego - San Diego
Massachusetts
- Massachusetts General Hospital - Boston
- University of Massachusetts Medical Center - Worcester
North Carolina
- University of North Carolina - Chapel Hill
- Unified Research Enterprise Brody School of Medicine at ECU - Greenville
Georgia
- Emory University - Atlanta
Michigan
- University of Michigan - Ann Arbor
Nebraska
- Quality Clinical Research, Inc. - Omaha
New York
- Alexandria Center for Life - NYC/ NYCEDC - New York
Pennsylvania
- Temple Univ School of Med - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2020-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04411628
The ClinicalTrials.gov registry entry for NCT04411628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04411628 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04411628 about?
NCT04411628 is a clinical study titled "A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19". The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation co...
What is the current status of trial NCT04411628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-05-28. Estimated completion is 2020-08-26.
What conditions does trial NCT04411628 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04411628?
The interventions under investigation include: Placebo (DRUG), LY3819253 (DRUG).
Who is sponsoring clinical trial NCT04411628?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04411628 being conducted?
This trial has 11 study locations across California, Georgia, Massachusetts, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
ACTIVE NOT RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.